Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Jul
18
Today In Oncology
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups
Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo